One meta-analysis found that positive molecular testing that targets, among other things, the CEA gene based on peritoneal fluid correlated with shorter OS and PRF (peritoneal recurrence-free survival) in gastric cancer patients [57]. The gene discussed is CEACAM5; the disease is gastric cancer.